 On October 11, 2011, the U.S. Food and Drug Administration (FDA) announced that dasatinib may increase the risk of a rare but serious condition in which there is abnormally high blood pressure in the arteries of the lungs (pulmonary hypertension, PAH).Symptoms of PAH may include shortness of breath, fatigue, and swelling of the body (such as the ankles and legs).In reported cases, people developed PAH after starting dasatinib, including after more than one year of treatment.